Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Association of EGFR c.2073A > T polymorphism with decreased risk of diffusely infiltrating astrocytoma in a Brazilian case-control study

Full text
Author(s):
Show less -
Barbosa, K. C. [1] ; Oba-Shinjo, S. M. [1] ; Uno, M. [1] ; Carvalho, Po. [1] ; Rosemberg, S. [2] ; Aguiar, Ph. P. [1] ; Carlotti, C. G. [3] ; Malheiros, S. M. F. [4] ; Toledos, S. [5] ; Lotufo, P. [6] ; Marie, S. K. N. [1]
Total Authors: 11
Affiliation:
[1] Univ Sao Paulo, Sch Med, Dept Neurol, BR-01246903 Sao Paulo - Brazil
[2] Univ Sao Paulo, Sch Med, Dept Pathol, BR-01246903 Sao Paulo - Brazil
[3] Univ Sao Paulo, Sch Med Ribeirao Preto, Div Neurosurg, Dept Surg, BR-14049 Ribeirao Preto - Brazil
[4] Univ Fed Sao Paulo, Dept Neurol, Sao Paulo - Brazil
[5] Univ Fed Sao Paulo, Pediat Oncol Inst, Dept Pediat, Sao Paulo - Brazil
[6] Univ Sao Paulo, Hosp Univ Sao Paulo, Sao Paulo - Brazil
Total Affiliations: 6
Document type: Journal article
Source: International Journal of Biological Markers; v. 23, n. 3, p. 140-146, JUL-SEP 2008.
Web of Science Citations: 5
Abstract

Epidermal growth factor receptor (EGFR) gene overexpression has been implicated in the development of many types of tumors, including glioblastomas, the most frequent diffusely infiltrating astrocytomas. However, little is known about the influence of the polymorphisms of EGFR on EGFR production and/or activity, possibly modulating the susceptibility to astrocytomas. This study aimed to examine the association of two EGFR promoter polymorphisms (c.-191C > A and c.-216G > T) and the c.2073A > T polymorphism located in exon 16 with susceptibility to astrocytomas, EGFR gene expression and survival in a case-control study of 193 astrocytoma patients and 200 cancer-free controls. We found that the variant TT genotype of the EGFR c.2073A > T polymorphism was associated with a significantly decreased risk of astrocytoma when compared with the AA genotype {[}sex- and age-adjusted odds ratio 0.51, 95% confidence interval 0.26-0.98]. No association of the two promoter EGFR polymorphisms (or combinations of these polymorphisms) and risk of astrocytomas, EGFR expression or survival was found. Our findings suggest that modulation of the EGFR c.2073A > T polymorphism could play a role in future therapeutic approaches to astrocytoma. (Int J Biol Markers 2008; 23: 140-6) (AU)

FAPESP's process: 04/12133-6 - Search for molecular markers related to the diagnosis and prognosis of tumors of the central nervous system
Grantee:Suely Kazue Nagahashi Marie
Support Opportunities: Research Projects - Thematic Grants